Tumor Suppressor Gene XEDAR Promotes Differentiation and Suppresses Proliferation and Migration of Gastric Cancer Cells Through Upregulating the RELA/LXRα Axis and Deactivating the Wnt/β-Catenin Pathway

Xinwu Zhang¹, Di Zhang¹, Xiaoli Sun¹, Shunle Li¹, Yun Sun¹, and Hongjun Zhai¹

Abstract
X-linked ectodermal dysplasia receptor (XEDAR) is a new member of the tumor necrosis factor receptor (TNFR) family that induces cell death. The purpose of this study is to determine the tumor-suppressive potential of XEDAR in the development and differentiation of gastric cancer (GC). XEDAR levels were analyzed in human GC tissues and adjacent normal tissues by immunohistochemistry (IHC), quantitative real-time reverse transcription PCR (RT-qPCR), and Western blot analysis. We found that XEDAR expression was significantly downregulated in GC tissues and further decreased in low differentiated GC tissues. Overexpression of XEDAR in MKN45 and MGC803 cells suppressed the ability of cell proliferation and migration, whereas silencing XEDAR showed the opposite effect. Additionally, XEDAR silencing resulted in the upregulation of the differentiation molecular markers β-catenin, CD44 and Cyclin D1 at the protein levels, whereas XEDAR overexpression showed the opposite effect. Notably, XEDAR positively regulated the expression of liver X receptor alpha (LXRα) through upregulating the RELA gene that was characterized as a transcription factor of LXRα in this study. Inhibition of LXRα by GSK2033 or activation of the Wnt/β-catenin pathway by Wnt agonist 1 impaired the effect of XEDAR overexpression on differentiation of MKN45 cells. Moreover, inhibition of RELA mediated by siRNA could promote cell proliferation/migration and rescue the effect of XEDAR overexpression on cell behaviors and expression of genes. Subsequently, overexpression of XEDAR suppressed the growth of GC cells in vivo. Taken together, our findings showed that XEDAR could promote differentiation and suppress proliferation and invasion of GC cells.

Keywords
X-linked ectodermal dysplasia receptor (XEDAR), RELA/LXRα, transcriptionally regulation, Wnt/β-catenin signaling pathway, gastric cancer

Introduction
Gastric cancer (GC) is one of the most common gastrointestinal neoplasm worldwide and the second biggest health burden in China¹,². The poor prognosis depends on gastric mucosal infiltration and metastatic spread to regional lymph nodes³.

The poor differentiation of tumor cells is often associated with a worse prognosis, including tumor metastasis and epithelial mesenchymal transition (EMT)⁴, especially in leukemia, colorectal cancer and GC. The canonical Wnt/β-catenin
signaling pathway governs a myriad of biological processes including regulation of stem cell self-renewal, cell proliferation, differentiation, and apoptosis. This signaling pathway is reprogrammed and activated in various low differentiated tumor tissues, and the activation of Wnt/β-catenin signaling could block tumor cell differentiation possibly by suppressing expression of differentiation-specific genes. Moreover, a couple of recent studies demonstrated that the nuclear hormone receptor liver X receptor alpha (LXRα) could promote cell differentiation in GC cells through suppressing the Wnt/β-catenin signaling pathway.

It has been widely identified that the tumor necrosis factor receptor (TNFR) family members play a crucial role in many physiological and pathological responses. X-linked ectodermal dysplasia receptor (XEDAR) is identified as a new ligand of the TNFR family that has been shown to be highly expressed in ectodermal derivatives during embryonic development and binds to ectodysplasin-A2 (EDA-A2). A prognostic value of XEDAR expression in tumor tissues has been reported and low expression of XEDAR has been demonstrated in a variety of cancers. In colorectal cancer, the XEDAR expression is suppressed due to either its epigenetic alterations and/or p53 mutations and correlated with tumor proliferation and differentiation. Although XEDAR lacks a discernible death domain that was associated with the induction of apoptosis by the death receptors of the TNFR family, it could nevertheless induce apoptosis when overexpressed in 293 T-cells. Furthermore, XEDAR has been shown to induce ectodermal differentiation via activating the nuclear factor kappa-B (NF-κB), c-Jun N-terminal kinase (JNK), and extracellular signal-related kinase (ERK) signaling pathways.

Based on these premises and considering that the expression and the biological function of XEDAR in GC cell differentiation have not been investigated so far, in this report, we investigated the expression and signaling activities of XEDAR in GC cells. We reported that XEDAR induced GC cells differentiation through upregulation of LXRα and deactivation of the Wnt/β-catenin signaling pathway. Our results suggest that XEDAR may represent a promising agent for the gene therapy of GC.

Materials and Methods

**Human GC Tissues and Cell Lines**

GC tissues (n = 69) and gastritis tissues (n = 30) were collected after surgical resection at the Department of General Surgery of the Second Affiliated Hospital of Xi’an Jiaotong University (Xi’an, China). Clinicopathological information of the 69 GC patients was shown in Table 1. Each sample was divided into two parts, the one was immediately snap-frozen in liquid nitrogen and stored at –80°C for RNA and protein extraction and the other was blocked in wax for histological analysis. This study was subject to approval by the Ethics Commitment of Xi’an Jiaotong

| Sex     | Age (years) | Degree of differentiation |
|---------|-------------|---------------------------|
| Female  | 43          | Moderately low            |
| Male    | 64          | Moderately low            |
| Male    | 57          | Moderately low            |
| Male    | 51          | Moderately low            |
| Male    | 61          | Moderately low            |
| Male    | 56          | Moderately low            |
| Male    | 50          | Moderately low            |
| Male    | 68          | Low                       |
| Male    | 53          | Low                       |
| Female  | 68          | Low                       |
| Male    | 73          | Low                       |
| Female  | 70          | Low                       |
| Male    | 45          | Low                       |
| Female  | 73          | Low                       |
| Male    | 68          | Low                       |
| Male    | 40          | Low                       |
| Male    | 63          | Low                       |
| Male    | 67          | Low                       |
| Female  | 58          | Moderately low            |
| Male    | 63          | Moderately low            |
| Female  | 55          | Moderately low            |
| Male    | 48          | Moderately low            |
| Female  | 73          | Moderately low            |
| Male    | 64          | Moderately low            |
| Female  | 58          | Moderately low            |
| Male    | 71          | Moderately low            |
| Female  | 63          | Low                       |
| Male    | 35          | Low                       |
| Female  | 61          | Low                       |
| Female  | 48          | Low                       |
| Female  | 58          | Low                       |
| Male    | 73          | Moderate                   |
| Male    | 65          | Moderate                   |
| Male    | 58          | Moderate                   |
| Male    | 70          | Moderate                   |
| Male    | 70          | Moderate                   |
| Male    | 20          | Moderate                   |
| Male    | 62          | Moderate                   |
| Female  | 74          | Moderately high            |
| Female  | 43          | Moderately high            |
| Female  | 68          | Moderately high            |
| Female  | 24          | Moderately high            |
| Male    | 66          | High                      |
| Male    | 65          | Moderate                   |
| Male    | 58          | Moderate                   |
| Male    | 30          | Moderate                   |
| Male    | 46          | Moderate                   |
| Male    | 50          | Moderate                   |
| Male    | 52          | Moderately high            |
| Female  | 64          | Moderately high            |
| Male    | 58          | Moderately high            |
| Male    | 55          | Moderately high            |
| Male    | 53          | Moderately high            |
| Male    | 42          | Moderately high            |
| Male    | 62          | Moderately high            |
| Female  | 67          | Moderately high            |
| Male    | 47          | Moderately high            |

(continued)
Table 1 (continued)

| Sex  | Age (years) | Degree of differentiation |
|------|-------------|---------------------------|
| 58   | Male        | 49                        | High                      |
| 59   | Male        | 62                        | High                      |
| 60   | Female      | 44                        | High                      |
| 61   | Male        | 38                        | High                      |
| 62   | Male        | 72                        | High                      |
| 63   | Male        | 71                        | High                      |
| 64   | Male        | 39                        | High                      |
| 65   | Male        | 62                        | High                      |
| 66   | Female      | 74                        | High                      |
| 67   | Male        | 63                        | Moderate                  |
| 68   | Male        | 75                        | Moderate                  |
| 69   | Male        | 64                        | Moderate                  |

University (Approval number: 17XJTU032) and written informed consent from the donor was obtained for the use of samples in this research.

The human GC cell lines (MKN45, HGC27, MGC803, and AGS) and the human gastric epithelial cell line (GES-1) were purchased from the Fourth Military Medical University (Xi’an, China). AGS cells were cultured in F-12 medium (Gibco Life Technologies, Grand Island, NY), and MKN45, HGC27, MGC803 and GES-1 cells were cultured in RPMI (Gibco Life Technologies, Grand Island, NY), and MKN45, HGC27, MGC803 and GES-1 cells were cultured in RPMI (Gibco Life Technologies, Grand Island, NY) with 10% fetal bovine serum (FBS, Gibco Life Technologies, Grand Island, NY) with 10% penicillin and streptomycin (North China Pharmaceutical Company, Ltd., China) in 5% carbon dioxide-air at 37°C. Cells were plated onto wells of 6-well plates.

**Histopathological Analysis**

After fixing GC tissue samples with 4% paraformaldehyde (PFA), ethanol gradient, and dimethylbenzene was used for deparaffin. The samples were embedded in paraffin and then sectioned (~4 μm) onto glass slides for hematoxylin and eosin (H&E) staining. After the same treatment of xenograft tumor tissues, the samples were also used to perform H&E staining. Immunohistochemical staining was performed using SP-9000 SPlink Detection Kits (Biotin-Streptavidin HRP Detection Systems, Zsbio Commerce Store; Beijing, China) according to the manufacturer’s instructions. The primary antibody was rabbit antihuman XEDAR (Bio-Rad, Hercules, CA, USA; AHP1182: 1:1000). Tissue sections of adjacent, moderate/high differentiation and low differentiation were deparaffinized with xyloil and dehydrated with ethanol. Endogenous peroxidase activity was quenched by incubating the slides in a solution of 700 μl H2O2 (30%) in 70 ml methanol. The sections were pretreated with pepsin (0.4%) for 30 min at 37°C. Blocking was done with normal serum. The slides were incubated with diaminobenzidine tetrahydrochloride (DAB) (Sigma, St. Louis, MO, USA) as substrate and counterstained with hematoxylin (Merck Eurolab Dietikon, Switzerland). The images were captured under a Nikon light microscope.

**RNA Extraction and Quantitative Real-Time Reverse Transcription PCR (RT-qPCR)**

Total RNA was extracted using TRIzol Reagent (Invitrogen, Carlsbad, CA, USA), and cDNA was synthesized from 2 μg of RNA using the PrimeScript™ RT Reagent Kit (Takara Biotechnology, Dalian, China) according to the manufacturer’s instructions. The primers used to amplify a 180-bp XEDAR cDNA fragments were 5’-GTT TGC CCA GGT TCT ACC GA-3’ and 5’-GCT CAC CAG TGC AAC AAG TG-3’. GAPDH was regarded as a loading control (primer sequences are 5’-GGA GCG AGA TCC TTC CTC CAA AAT-3’ and 5’-GGC TGT TGT CAT ACT TCT CAT GG-3’). Other primer sequences applied in the analyses for expression mRNA levels are as follows: RELA (5’-ATG TGA AGA TCA TTA AGC AGC-3’ and 5’-CCT GGT CCT GTG CCT TTG TAG CCA TT-3’), LXRα (5’-CCT TCA GAA CCC ACG GAC ATC C-3’ and 5’-AGG CTG CAT AGC TCG TTC C-3’), CD44 (5’-CTG CCG CTT TGG AGG TGT A-3’ and 5’-CAT TGT GGG CAA GGT GCT ATT-3’), CyclinD1 (5’-GCT GGG CAC AAG TGG AAC AAA CCA TC-3’ and 5’-CCT CCT TCT GCA CAC ATT TGA A-3’), and β-catenin (5’-TTG AAG GTT GTA CCG GAG CC-3’ and 5’-CAG CTT CCT TGT CCG GAG CA-3’). RT-qPCR was conducted using SYBR Premix Ex Taq™ (Takara, Dalian, China) at 95°C for 3 min, followed by 35 cycles of 95°C for 15 s and 60°C for 34 s in the ABI StepOnePlus Real-time PCR system. The relative fold changes in mRNA expression were calculated using the 2−ΔΔCT method.

**Protein Extraction and Western Blot Analysis**

Whole protein extracts were lysed in ice-cold radioimmunoprecipitation assay (RIPA) lysis buffer containing cocktails of protease and phosphatase inhibitors (Sigma, St. Louis, MO, USA) according to the manufacturer’s protocol. Total proteins from each lysate were separated by sodium dodecyl sulphate-polyacrylamide gel electrophoresis (SDS-PAGE) and transferred onto polyvinylidene fluoride (PVDF) membranes and then blocked with 5% nonfat milk for 1 h. The membranes were then probed with the indicated primary antibodies at 4°C with gentle shaking overnight and incubated with horseradish peroxidase- (HRP-) conjugated secondary antibodies. Then, the proteins were visualized by chemiluminescence, and signals were quantified by Image J software. Antibodies used in this study are as follows: XEDAR (Bio-Rad, Hercules, CA, USA; AHP1182); LXRα (Abcam, Cambridge, UK; ab41902); RELA (Abcam, Cambridge, UK; ab16502); CD44 (Cell Signaling Technology (CST), Boston, MA, USA; 37259); CyclinD1 (CST, Boston, MA, USA; 3195); β-catenin (CST, Boston, MA, USA; 9562); EGFR (Abcam, Cambridge, UK; ab25894); FXOM1 (Abcam, Cambridge, UK; ab207298); N-cadherin (CST, Boston, MA, USA; 4061); E-cadherin (CST, Boston, MA, USA; 3195); Snail (CST, Boston, MA, USA; 3879); GAPDH (CST, Boston, MA, USA; 5174). The dilution factor for antibodies was 1:1,000.
XEDAR Gene Knockdown and Transfection

Three XEDAR short interfering RNA (siRNA1, siRNA2, and siRNA3) and three RELA short interfering RNA (siRNA1, siRNA2, and siRNA3) molecules used in this study were designed and synthesized by MyBioSource (San Diego, CA, USA). For nonsense control siRNA (Scramble), an irrelevant siRNA with random nucleotides and unknown specificity was used. Briefly, MKN45 and MGC803 cells (70% of confluence) were transfected with siRNA for XEDAR using the siPORT NeoFX transfection agent (Ambion, Austin, TX, USA). The siRNA/transfection agent was dispensed into culture plates as specified by the manufacturer. After transfection for 48 h, silencing efficiency was evaluated by RT-qPCR and Western blot analysis.

Construction and Transfection of Overexpression Vectors pcDNA-XEDAR and pcDNA-RELA

A pair of primers for the known XEDAR and RELA coding sequences was designed as mentioned earlier. The RT-qPCR using the following conditions: 95 °C for 5 min, and followed by 30 cycles of 95 °C for 30 s, 60 °C for 30 s, then 72 °C for 60 s, and 72 °C for 7 min. Y8H-mutant (Y8 H) XEDAR was generated using the QuickChange site-directed mutagenesis kit (Stratagene). The target genes were connected to pcDNA3.1 (+). The pcDNA3.1 (+) without the target genes was a negative control (Vector). pcDNA3.1 (+)-XEDAR (pcDNA-XEDAR), pcDNA3.1 (+)-RELA (pcDNA-RELA), pcDNA3.1 (+)-EDA-A2 (pcDNA-EDA-A2) or pcDNA3.1 (+)-Y8H-XEDAR (pcDNA/ Y8H-XEDAR) was transfected into MKN45 cells (6-well plate, 1 × 10^5/well) with different concentrations (0.1 µg/ml, 0.5 µg/ml and 1 µg/ml). After transfection for 48 h, overexpression efficiency was evaluated by RT-qPCR and Western blot analysis.

Cell Proliferation Assay

For cell proliferation assays, Ethynyl-2-deoxyuridine (EdU) incorporation assays were performed. MKN45 or MGC803 cells were seeded in 6-well chamber slides (1 × 10^5/well), and cells were placed in medium without serum and phenol red on the next day. After 24 h incubation, cells were treated with DMSO (100 nM) in the absence or presence of 5% FBS in phenol red free medium for another 24 h. EdU (10 µM, Invitrogen, Carlsbad, CA, USA) was added to the medium for the last 4 h of the treatment. EdU incorporation was assayed using Click-it EdU Alexa Fluor® 488 Cell Proliferation Assay Kit (Invitrogen, Carlsbad, CA, USA). Cell fixation, permeabilisation, and EdU detection were performed according to the manufacturer’s instructions. 4',6-Diamidino-2-phenylindole (DAPI) staining was used to identify nuclei for determination of cell number. EdU and DAPI signals were captured with a Zeiss Axiovert 100 M fluorescence microscope, and captured images were processed and analyzed with ImageJ software. The EdU and DAPI signals for each sample were analyzed in six different fields. The relative intensity of the EdU signal was calculated by normalizing the fluorescence signal of EdU with the DAPI staining.

Cell Counting Kit-8 (CCK-8; Dojindo, Kumamoto, Japan) was also used to measure the GC cell proliferation. Each group of MKN45 cells in logarithmic phase was prepared into a single-cell suspension, and the cell density adjusted at 1,000 cells/well were seeded in a 96-well plate. Then, the CCK-8 reagent (10 µl) was added into each well for additional 2 h in the darkness. The blank control well only contained the medium and CCK-8 solution. Finally, a microplate reader at a wavelength of 450 nm was applied to detect absorbance (OD) values.

Colony Formation Assay

Following transfection, MKN45 or MGC803 cells were seeded into 6-well plates at a density of 1,000 cells/well, and the plates were shaken to distribute the cells equally followed by incubation at 37 °C in a humidified incubator (5% CO2). After cultured for 14 days, the cells were washed with PBS, fixed with 4% paraformaldehyde at room temperature for 2 h, and then stained with crystal violet (Thermo Fisher Scientific) for 30 min. Following three times washing with phosphate-buffered saline, the colonies were counted using an IX83 phase contrast microscope (Olympus Corporation, Tokyo, Japan) and five fields were selected for colony counting. Each well was assessed in triplicate.

Cell Migration Assay

Cell migration was assessed using the Transwell chambers (pore size, 8.0 µm; Corning, New York, USA). MKN45 or MGC803 cells were resuspended in serum-free RPMI medium, then cell suspensions (200 µl containing 50,000 cells) were seeded onto the filters in 24-well chambers; 750 µl of medium containing 10% FBS was placed in the lower chambers as a chemoattractant. The cells were allowed to migrate for 24 h at 37 °C. Cells remaining on the upper surface of the membrane were removed using a cotton swab. The filters were fixed with 4% paraformaldehyde, and the cells were stained with 0.1% crystal violet solution. The cells that had migrated from the upper to the lower side of the filter were counted in six randomly selected fields per sample.

Chromatin Immunoprecipitation (ChIP) Assay

Chromatin Immunoprecipitation (ChIP) assay was performed by using ChIP-IT Expression Chromatin Immunoprecipitation Kits (Active motif, Carlsbad, CA, USA). Cells were treated by formaldehyde for 10 min, lysed by Glycine Stop-Fix solution, and sonicated to achieve 100 ~ 500 bp DNA fragments. The immuno-complexes were precipitated using antibodies against RELA and normal serum IgG
(as negative control) under overnight rotationally incubation at 4°C. 30% amount of chromatin without antibody incubation was used as the input control. The reaction mixtures were eluted using beads following the manufacturer’s protocol and then applied in the following quantitative PCR analysis.

**Luciferase Reporter Assays for LXRα Transcriptional Activity Determination**

Dual-luciferase reporter assay was used to evaluate the transcription regulatory activity of RELA on LXRα gene. Briefly, RELA response element (RELA RE) and either wild-type or mutated LXRα luciferase reporter vectors were transfected into the MKN45 cells, followed by the stimulation with 500 U/ml IL-2 alone or together with 10 μM JSH-23 for 24 h. In another experiment, the RELA response element (RELA RE) and either wild-type or mutated LXRα luciferase reporter vectors were transfected into MKN45 cells overexpressing XEDAR, and then the cells were treated with JSH-23. Finally, the luciferase activity was determined with a Promega kit (Promega, Madison, WI) and Multiskan FC Microplate Reader (Thermo Fisher Scientific, Waltham, MA, USA).

**Tumor Xenograft Assay**

BALB/c nude mice (weight, 22–24 g; age, 8 weeks; Shanghai SLAC Laboratory Animal Co., Ltd.) were subcutaneously injected with 1×10^7 Vector or pcDNA XEDAR stably transfected MKN45 cells in the right side of the back to establish the subcutaneous xenograft tumor model. Briefly, the mice were randomly divided into two groups (eight per group). Every five days, the length and width of the tumors with a digital Vernier caliper were measured to calculate the tumor volume using the following formula: volume = 0.5 × Length × Width^2. After 7 weeks later, the mice were euthanized, the subcutaneous tumors were resected, and the tumor volume and weight were recorded. Then, the tumors were fixed with 4% paraformaldehyde. All the animal experiments were performed in accordance with guidelines approved by the Animal Experimentation Ethics Committee of the Second Affiliated Hospital of Xi’an Jiaotong University.

**Statistical Analysis**

The data are expressed as means ± SEM and each experiment were performed in triplicate in this study. Survival data were estimated using the Kaplan–Meier method and compared using the long-rank test. The differences in means for paired observations were analyzed by Student’s t test. Significance of the variance between multiple groups was analyzed by one-way ANOVA. A significant difference was indicated when the P-value < 0.05.

**Results**

**XEDAR Expression is Downregulated in GC Tissues and Intimately Associated with Differentiation of GC Cells**

To assess potential roles of XEDAR, we first determined the XEDAR expression levels and distribution locations in GC tissues and tumor adjacent tissues by H&E staining, immunohistochemistry, RT-qPCR and Western blot analysis (Fig. 1A–D). The expression of XEDAR was significantly lower in moderately/high differentiated GC tissues than tumor adjacent tissues (Fig. 1B–D). Similarly, the mRNA and protein expression levels of XEDAR were remarkably downregulated in GC cell lines (MKN45, HGC27, MGC803, and AGS) compared with the normal human gastric epithelial cell line (GES-1) (Fig. 1F, G). Simultaneously, moderately/high differentiated GC tissues-derived XEDAR protein was mostly located in the cytoplasm while tumor adjacent tissues-derived XEDAR protein was expressed on the cell membrane (Fig. 1B). XEDAR expression was significantly reduced in low differentiated GC tissues compared with moderately/high differentiated GC tissues (Fig. 1B–D). And low differentiated GC tissues derived XEDAR protein was sparingly expressed in the cytoplasm and the cell membrane (Fig. 1B). Subsequently, we examined the relationship between XEDAR expression level and patient survival in GC, and Kaplan–Meier curves showed that patients with low expression of XEDAR is associated with poor overall survival (OS) (Fig. 1E).

**XEDAR Negatively Regulates Cell Proliferation and Migration in GC Cells**

To investigate the effect of XEDAR on the proliferation and migration of GC cells, MKN45 cells were transfected with different concentrations (0.1 μg/ml, 0.5 μg/ml, and 1 μg/ml) of pcDNA-XEDAR. Total RNA and protein were isolated and analyzed by RT-qPCR or Western blot analysis. Compared with control, the expression of XEDAR was increased by all three different concentrations of pcDNA-XEDAR at both mRNA (Fig. 2A) and protein levels (Fig. 2B). The overexpression efficiency was the most obvious when the transfection concentration was 1 μg/ml. Next, to examine the importance of XEDAR in GC cell proliferation and migration, we performed EdU and Transwell assay, respectively. Overexpression of XEDAR in MKN45 cells suppressed the ability of cell proliferation and migration (Fig. 2C, D). Besides that, the effects of XEDAR overexpression on regulating colony formation of MKN45 cells were also investigated. And the results showed that XEDAR overexpression significantly repressed the colony formation of MKN45 cells in a dose-dependent manner (Fig. 2E). And the suppressing efficiency was the most obvious when the transfection concentration was 1 μg/ml. Hence, 1 μg/ml
of pcDNA-XEDAR was selected for subsequent transfection experiments.

XEDAR was shown to promote apoptotic signaling through the binding of its ligand EDA-A2. Then, we carried out some experiments by overexpressing EDA-A2 and/or mutated XEDAR (Y8H-XEDAR) that could not bind EDA-A2 to make the suppressive effect of XEDAR more convincing. We found that the expression level of XEDAR protein on the cell membrane was significantly increased in cells transfected with EDA-A2 overexpression plasmid, but remarkably decreased in cells transfected with Y8H-XEDAR expression plasmid. And co-transfection with EDA-A2 overexpression and Y8H-XEDAR expression plasmids reversed the promoting effect of EDA-A2.

---

**Figure 1.** Expression of XEDAR in different differentiation of GC tissues and adjacent normal tissues. Representative micrographs of (A) H&E staining and (B) immunohistochemistry (IHC) for expression of XEDAR in 30 gastritis tissues (Control), 38 moderately/high differentiated GC tissues and 31 low differentiated GC tissues. The images were at a magnification of ×100. (C) RT-qPCR analysis for the expression of XEDAR mRNA in 30 gastritis tissues (Control), 38 moderately/high differentiated GC tissues and 31 low differentiated GC tissues. (D) Western blot was used to detect the relative expression level of XEDAR protein in Control, moderately/high differentiated GC tissues and low differentiated GC tissues. (E) Kaplan–Meier overall survival analyses were used to investigate the relationship between XEDAR expression and GC patient survival. (F and G) RT-qPCR and Western blot was respectively performed to determine the mRNA and protein expression of XEDAR in GC cell lines and normal gastric epithelial cell line. *P < 0.05 (vs. Control), #P < 0.05 (vs. Moderate/high differentiation).
overexpression on XEDAR expression (Supplemental Figure S1A). The results of the CCK-8 assay indicated that the EDA-A2 overexpression significantly suppressed cell viability, while Y8H-XEDAR had no obvious effect on cell growth, indicating that membrane localization is critical for XEDAR signaling (Supplemental Figure S1B).

To further validate the elevated expression of XEDAR played a critical role in the proliferation and migration of GC cells, MKN45 cells were respectively transfected with three different XEDAR siRNA at the concentration of 40 nM for 48 h. RT-qPCR and Western blot analysis revealed that the level of XEDAR was reduced by all the three XEDAR siRNAs, and the XEDAR siRNA1 had the most obvious inhibition efficiency on XEDAR (Fig. 3A, B). Thus, XEDAR siRNA1 was selected for subsequent transfection experiments. Apart from that, we also performed XEDAR knockdown experiment in HGC27 cell line, and found that the difference in the interference efficiency of XEDAR siRNA between MKN45 cell line and HGC27 cell line was not obvious (Supplemental Figure S2A, B). Therefore, MKN45 cell line was used in subsequent trials to ensure the uniformity of experiments. In addition, we found that XEDAR siRNA transfection significantly facilitated the proliferation and migration of MKN45 cells compared with scrambled siRNA (Fig. 3C, D). Gain- and loss-of-function manipulations were also performed in another GC cell line MGC803. The results showed that XEDAR also

Figure 2. XEDAR Overexpression Inhibits Cell Proliferation and Migration in GC Cells. MKN45 cells (1.0 × 10^5/cm²) were transfected with control pcDNA3.1 (+) (vector) and different concentrations (0.1 μg/ml, 0.5 μg/ml, and 1 μg/ml) of pcDNA3.1 (+)-XEDAR (pcDNA-XEDAR) for 48 h. (A) RT-qPCR analysis for XEDAR mRNA expression in MKN45 cells. (B) Western blot analysis for XEDAR protein levels in MKN45 cells. (C) The proliferation of MKN45 cells was evaluated by EdU (5-ethynyl-2-deoxyuridine) assay. (D) The migration of MKN45 cells was assessed by Transwell migration assay. (E) The colony formation of MKN45 cells was assessed by plate colony formation assay.

*P < 0.05 (vs. Vector). **P < 0.05 (vs. 0.1 μg/ml of pcDNA-XEDAR).
negatively regulated cell proliferation, migration and colony formation in MGC803 cells (Supplemental Figure S3).

**Wnt/β-Catenin Signaling is Essential for the XEDAR-Mediated Differentiation of GC Cells**

The Wnt/β-catenin signaling is well known to play an important role in the process of cell differentiation. CD44 and Cyclin D1, downstream targets of the Wnt/β-catenin signaling, are specific markers for cell differentiation. Our findings showed that the mRNA and protein levels of CD44, Cyclin D1 and β-catenin were decreased respectively in MKN45 cells transfected with pcDNA-XEDAR (Fig. 4A, B). Conversely, the opposite results were assayed when XEDAR silencing (Fig. 4A, B). Moreover, we also detected the expression of markers of gastric epithelial maturation differentiation (ATP4A, ATP4B, MIST1, Pepsinogen I, GAST, TFF1, and GKN1) and markers of gastric epithelial dedifferentiation (Villin and SOX9) (Fig. 4C, D). As shown in Fig. 4E, we detected the expression levels of EMT markers including N-cadherin, Vimentin, and E-cadherin in GES-1 cells, as well as in the MKN45 cells transfected with XEDAR overexpression vector or XEDAR siRNA. The results showed that the EMT process was significantly promoted in MKN45 cells compared with GES-1 cells, and overexpression of XEDAR enhanced the EMT of MKN45 cells (Fig. 4E). Consistently, XEDAR also negatively regulated cell proliferation/migration and expression of CD44, Cyclin D1 and β-catenin, and positively
regulated LXR<sub>a</sub> expression and cell differentiation in MGC803 cells (Supplemental figure S3A). Thus, all above data suggested that XEDAR could promote GC cell differentiation through regulating Wnt/β-catenin signaling pathway.

**XEDAR Promotes Differentiation of GC Cells via Upregulating LXR<sub>a</sub> and Deactivating the Wnt/β-Catenin Signaling Pathway**

LXR<sub>a</sub> is a crucial nuclear hormone receptor and plays a vital role in cell differentiation. And our results found that XEDAR overexpression obviously activated the expression of LXR<sub>a</sub> in MKN45 cells (Fig. 5A). Thus, we then tested whether XEDAR regulate GC cells migration and differentiation via regulating LXR<sub>a</sub> or and the Wnt/β-catenin signaling pathway. Strikingly, the results revealed that inhibition of LXR<sub>a</sub> by its specific antagonist GSK2033 or activation of the Wnt/β-catenin signaling pathway by the Wnt agonist 1 upregulated the expression of CD44, Cyclin D1 and β-catenin proteins in “Vector”, “XEDAR”, “Scramble” and “siXEDAR” groups cells. (C) and (D) RT-qPCR analysis determined the relative expression of CD44, Cyclin D1 and β-catenin in “Vector”, “XEDAR”, “Scramble” and “siXEDAR” groups cells. (E) Western blot analysis determined the relative expression of EMT-related proteins (E-cadherin, N-cadherin, and Snail) in transfected MKN45 cells. *P < 0.05.

** Figure 4. Effects of XEDAR on Wnt/β-catenin signaling pathway in MKN45 cells.** MKN45 cells (1.0 × 10<sup>5</sup>/cm<sup>2</sup>) were transfected with control siRNA (Scramble, 40 nM), specific siRNA against XEDAR (XEDAR siRNA, 40 nM), control pcDNA3.1(+) (vector, 1 µg/ml) or pcDNA-XEDAR (XEDAR, 1 µg/ml) for 48 h. RT-qPCR (A) and Western blot (B) analysis determined the relative expression of CD44, Cyclin D1 and β-catenin proteins in “Vector”, “XEDAR”, “Scramble” and “siXEDAR” groups cells. (C) and (D) RT-qPCR analysis determined the relative expression of markers of gastric epithelial maturation differentiation (ATP4A, ATP4B, MIST1, Pepsinogen I, GAST, TFF1, and GKN1) and markers of gastric epithelial dedifferentiation (Villin 1 and SOX9) in MKN45 cells transfected with pcDNA-XEDAR or XEDAR siRNA, respectively. (E) Western blot analysis determined the relative expression of EMT-related proteins (E-cadherin, N-cadherin, and Snail) in transfected MKN45 cells. *P < 0.05.

**RELA is a Transcription Factor of LXR<sub>a</sub>**

To further explore LXR<sub>a</sub> was regulated by which genes or factors, we analyzed LXR<sub>a</sub> gene structure and searching the
1,000-base sequences upstream and downstream its transcription initiation site (possible binding region of cis-acting elements). The output of ChIPBase (http://rna.sysu.edu.cn/chipbase/), a bioinformatics tool decoding the transcriptional regulatory networks of genes from ChIP-seq data, revealed that there is a conserved binding motif for the transcription factor RELA at \( +577 \) to \( +586 \) downstream the transcription initiation site of the LXR\(a\) gene (Fig. 6A). Chromatin immunoprecipitation (ChIP) combined with qPCR assays showed that high abundance of LXR\(a\) promoter sequence was detected in the DNA immunoprecipitated by the RELA antibody but not in that by IgG (Fig. 6B), indicating that RELA can directly bind to LXR\(a\) promoter. Moreover, IL-2 is an activator of the nuclear factor-\(\kappa\)B (NF-\(\kappa\)B) pathway. Thus, we examined the protein expression levels of LXR\(a\) in response to IL-2 treatment. As shown in Supplemental figure S4A, IL-2 therapy could remarkably upregulate LXR\(a\) protein level, which was consistent with the overexpression of XEDAR. Under IL-2 stimulation, the treatment of JSH-23, an inhibitor of RELA, caused a decrease in LXR\(a\) protein level (Supplemental Figure S4B). To further investigate the underlying mechanism, we performed luciferase reporter assay by establishing the LXR\(a\) luciferase reporter vectors containing the mutation binding sites (Supplemental figure S4C). We transfected these vectors into MKN45 cells followed by treating them with IL-2 alone or IL-2+JSH-23, and examined them for the transcriptional activity. The results showed that IL-2 remarkably upregulated the transcriptional activity of WT-LXR\(a\) vector, while JSH-23 treatment could eliminate this effect (Supplemental Figure S4D). However, IL-2 had no obvious effect on the promoter activity of MUT-LXR\(a\) vector (Supplemental Figure S4D). Furthermore, we also transfected cells with luciferase reporter and XEDAR overexpression vectors followed by the treatment with JSH-23, and we found the effect of EXARD overexpression on the transcriptional activity of LXR\(a\) was consistent with IL-2 (Supplemental Figure S4E). Then, the pcDNA-RELA expression vector at concentrations of 0.5 \(\mu\)g/ml and 1 \(\mu\)g/ml was transfected into MKN45 cells, and the effect of RELA overexpression on expression of LXR\(a\) and its downstream genes was evaluated by Western blot. The results showed that pcDNA-RELA transfection resulted in upregulation of RELA and LXR\(a\) protein levels and downregulation of...
CyclinD1 and β-catenin protein levels in a dose-dependent manner (Fig. 6C, D).

Inhibition of which Rescues the Effect of XEDAR Overexpression on Cell Behaviors and Expression of Genes Subsequently, to verify whether RELA was involved in the regulation of XEDAR on LXRα, we determined the inhibition efficiencies of RELA by respectively transfected MKN45 cells with three different RELA siRNAs. RT-qPCR (Fig. 7A) and Western blot (Fig. 7B) analyses revealed that the level of RELA was reduced by both three RELA siRNAs transfection, and the RELA siRNA2 had the highest efficiency. The mRNA levels of RELA and LXRα in MKN45 cells transfected with vector, 0.5 μg/ml pcDNA-XEDAR and 1 μg/ml pcDNA-XEDAR are shown in Figure 6C. (D) The protein levels of RELA, LXRα, CyclinD1 and β-catenin in MKN45 cells transfected with vector, 0.5 μg/ml pcDNA-XEDAR and 1 μg/ml pcDNA-XEDAR. *p < 0.05 (vs. Vector). **p < 0.05 (vs. 0.5 μg/ml of pcDNA-XEDAR).
most obvious inhibition efficiency of RELA. Hence, RELA siRNA2 was applied in the subsequent transfection experiments. Our results showed that RELA siRNA transfection suppressed expression of RELA and LXR
\(\alpha\) and promoted expression of CyclinD1 and \(\beta\)-catenin at both mRNA and protein levels but had no effect on XEDAR expression (Fig. 7C, D). In consistent with the change in gene expression, inhibition of RELA enhanced cell proliferation and migration in MKN45 cells (Fig. 7C–F). Moreover, as expected, RELA siRNA could rescue the effect of pcDNA-XEDAR on expression of the above genes and cell behaviors (Fig. 7C–F). Besides that, we also detected the overexpression efficiencies of RELA by respectively transfected MKN45 cells with 0.5 \(\mu\)g/ml or 1 \(\mu\)g/ml pcDNA RELA. The results indicated that the expression level of RELA was increased by pcDNA RELA transfection in a dose-dependent manner (Supplemental Figure S5A, B). Thus, 1 \(\mu\)g/ml of pcDNA RELA was applied in the subsequent transfection experiments. Subsequently, we investigated the effect of transfection with XEDAR siRNA and pcDNA RELA on the expression level of LXR\(\alpha\) in MKN45 cells, and the results showed that transfection with XEDAR siRNA alone significantly suppressed the LXR\(\alpha\) expression, while together with pcDNA RELA reversed this result (Supplemental Figure S5C). Furthermore, EGFR and FOXM1 were demonstrated to be downregulated by the LXR\(\alpha\), thus inhibiting the tumors growth including GC 16–18. Therefore, we detected the expression levels of EGFR and FOXM1 in MKN45 cells transfected with XEDAR overexpression vector

---

**Figure 7.** RELA mediates the regulation of XEDAR on LXR\(\alpha\) and negatively regulates cell proliferation and migration in MKN45 cells. RT-qPCR (A) and Western blot (B) analysis confirmed the interference efficiencies of three different RELA siRNAs. About 50 \(n\)M RELA siRNA2, which was described as RELA siRNA, was used to incubate with the MKN45 cells alone or together with 1 \(\mu\)g/ml pcDNA-XEDAR. After incubation for 48 h, the cells were harvested and applied into analyses as follows: (C) The mRNA levels of XEDAR, RELA, LXR\(\alpha\), CD44, CyclinD1 and \(\beta\)-catenin were detected with qPCR. (D) The protein levels of XEDAR, RELA, LXR\(\alpha\), CD44, CyclinD1 and \(\beta\)-catenin were detected with Western blot. (E) Cell proliferation and (F) cell migration was respectively evaluated by EdU and Transwell migration. (G) Western blot analysis determined the relative expression of EGFR and FXOM1 protein in transfected MKN45 cells. *\(P < 0.05\).
alone or together with RELA siRNA. The results showed that XEDAR significantly suppressed EGFR and FOXM1 expression, while silence of RELA weakened these inhibitory effects (Fig. 7G). These data indicated that RELA mediated the regulation of XEDAR on LXRα, inhibition of which rescued the effect of XEDAR overexpression on cell behaviors and expression of genes.

**XEDAR Inhibited Xenograft Tumor Growth of GC in Vivo**

To study the role of XEDAR in GC cell growth in vivo, we established the nude mouse subcutaneous xenograft models. The experiment consisted of two groups of mice: one injected with MKN-45-XEDAR cells and the other with MKN-45-Vector cells. The effect on tumor growth was assessed by measuring the tumor size every five days from the fifth day after injection. After tumor tissues were harvested (Fig. 8A), the tumor volumes and weight in mice injected with MKN-45-XEDAR cells were significantly decreased as compared with those in Vector group (Fig. 8B, C). The results of tumor tissues for HE staining showed that overexpression of XEDAR obviously suppressed the cell growth of GC in vivo (Fig. 8D). Moreover, Western blotting assay suggested LXRα expression was increased and β-catenin was decreased in tumor tissues in XEDAR group compared with those in control group (Fig. 8E). In conclusion, these results indicated that XEDAR inhibited xenograft tumor growth of GC in vivo.

**Discussion**

The occurrence and development of tumors are often linked to the loss of tumor suppressor genes. XEDAR is identified as a new tumor suppressor gene that has been shown to be highly expressed in ectodermal derivatives during embryonic development. Notably, XEDAR usually interacts with EDA-A2 that is a recently isolated ligand of the TNF family. The XEDAR protein is a three-type transmembrane protein with a molecular weight of 33 kD, which plays a normal physiological role on the cell membrane. Several studies demonstrate that XEDAR is abnormally expressed in various types of malignant tumors, such as breast cancer and colorectal cancer. In this study, the expression of XEDAR was determined using immunohistochemistry, RT-qPCR and Western blot analyses. We revealed that the expression levels of XEDAR in GC tissues were obviously lower than that in adjacent normal tissues and patients with low expression of XEDAR is associated with poor overall survival. Special attention was given to the properties of that the GC tissues-derived XEDAR protein was mostly located in the cytoplasm while tumor adjacent tissues-derived
XEDAR protein was expressed on the cell membrane. Emerging evidence has shown that the XEDAR protein is mainly involved in cell proliferation, differentiation, apoptosis, and various signaling pathways. It has been shown that XEDAR activated the NF-κB and JNK pathways in an EDA-A2-dependent fashion and XEDAR-induced JNK activation was mediated by TRAF3, TRAF6, and ASK1. As a colorectal tumor suppressor, XEDAR could mediate p53-regulated anokiasis pathway, and inactivation of XEDAR results in the enhancement of CRC cell adhesion and spreading. In addition, XEDAR is suppressed in osteosarcoma cell lines and adenoviral-mediated expression of EDA-A2 in these cells results in the induction of apoptosis via caspase activation and cell-cycle arrest in the G0/G1 phase. Here, we presented evidence that the expression levels of XEDAR were positively correlated with GC tumor differentiation. Simultaneously, XEDAR overexpression could inhibit GC cell proliferation and migration in MKN45 and MGC803 cells, whereas silencing XEDAR showed the opposite effect. Moreover, we found that transfected MKN45 cells with pcDNA-EDA-A2 resulted in a decrease in cell viability.

Based on the tumor cells differentiation plays an important role in the treatment of cancer and the mechanism of XEDAR affecting GC cell differentiation is unknown yet. The role of XEDAR as a tumor suppressor gene in GC cell differentiation was studied further. We found that silencing XEDAR resulted in the upregulation of the differentiation molecular markers β-catenin, CD44, and Cyclin D1 at the protein levels, whereas XEDAR overexpression showed the opposite effect. Moreover, activation of the Wnt/β-catenin pathway by Wnt agonist 1 impaired the effect of XEDAR overexpression on differentiation of MKN45 cells. The Wnt/β-catenin signaling pathway is one of the most important pathways for regulating cell differentiation. This signaling pathway has abnormal activation in various tumor tissues, such as gastric cancer, colorectal cancer, and hepatocellular carcinoma. Meanwhile, as a key role of the Wnt/β-catenin signaling pathway, β-catenin protein is higher in GC tissues than that in normal gastric mucosal tissue. Furthermore, several studies demonstrate that CD44 and CyclinD1 are the target genes of the Wnt/β-catenin signaling pathway, which is involved in the regulation of cell differentiation. Upregulation of CD44 and Cyclin D1 is also found in various cancer cells or tissues including GC. Our results indicated that XEDAR could deactivate the Wnt/β-catenin signaling pathway and further inhibit CD44 and Cyclin D1 in GC cells. LXRα has a vital role in cell differentiation. It is reported that LXRα regulated differentiation of hepatocyte-like cells via reciprocal regulation of HNF4α. And it inhibits adipocyte differentiation of mesenchymal stem cells with the Wnt/β-catenin signaling pathway. An emerging literature show that LXRα promoted GC cell differentiation through deactivating the Wnt/β-catenin signaling. In our study, XEDAR overexpression activated the expression of LXRα in MKN45 cells. Moreover, inhibition of LXRα by GSK2033 impaired the effect of XEDAR overexpression on differentiation of MKN45 cells.

The RELA protein, also named p65, is famous as an important member of the transcription factor family nuclear factor kappa-B (NF-κB) that play important roles in inflammation and tumorigenesis. In almost everyone’s knowledge, RELA directly promotes the transcription of a variety of oncogenes and plays a promoting role in tumorigenesis and cancer progression. However, in our current study, RELA was identified as a transcription factor of the tumor suppressor gene LXRα and a negative regulator of the Wnt pathway that is a proto-carcinomatous pathway contributing to proliferation, invasion, metastasis, drug resistance and angiogenesis in tumor cells. We showed that RELA mediated the regulation of XEDAR on LXRα and inhibition of RELA rescued the effect of XEDAR overexpression on cell behaviors and expression of genes. In fact, a few of previous studies also indicate that sometimes RELA also play an anticancer role. For example, in human cervical cancer cell line Hela and mouse colorectal cancer cell line CT26, NF-κB is found to be stimulated by the mitochondrial outer membrane permeabilisation (MOMP), a typical cancer cell killer, and to downregulate the inhibitor of apoptotic proteins. Moreover, similar to our study, a couple of studies reveal that XEDAR could upregulate the NF-κB family members including RELA.

In conclusion, our findings showed that XEDAR expression was frequently downregulated in GC tissues and intimately associated with differentiation of GC. The expression levels of XEDAR were positively correlated with GC tumor differentiation and negatively correlated with GC cell proliferation and migration. Notably, XEDAR promoted differentiation of GC cells through upregulation of LXRα and deactivation of the Wnt/β-catenin pathway. These results may have considerable implications for the diagnosis and treatment of GC.

Acknowledgments
The authors wish to express their sincere thanks to all those who have lent their hands in the course of writing this paper.

Ethical Approval
This study was approved by the Ethics Committee at the Second Affiliated Hospital of Xi’an Jiaotong University (Xi’an, China).

Statement of Human and Animal Rights
All procedures in this study were conducted in accordance with the Second Affiliated Hospital of Xi’an Jiaotong University Of ETHICS COMMITTEE’S (APPROVAL NUMBER: 2020076) approved protocols.

Statement of Informed Consent
Written informed consent was obtained from the patients for their anonymised information to be published in this article.
Declarations of Conflicting Interests
The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Funding
The author(s) received no financial support for the research, authorship, and/or publication of this article.

ORCID iD
Hongjun Zhai https://orcid.org/0000-0002-0714-3990

Supplemental Material
Supplemental material for this article is available online.

References
1. Chen W, Zheng R, Baade PD, Zhang S, Zeng H, Bray F, Jemal A, Yu XQ, He J. Cancer statistics in China, 2015. CA Cancer J Clin. 2016;66(2):115–132.
2. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65(2):87–108.
3. Vycital O, Dubova M, Palek R, Hosek P, Branzovsky J, Treska V, Daum O, Liska V. The Impact of immune interaction on the metastatic infiltration of colorectal carcinoma to lymph nodes. Anticancer Res. 2018;38(7):4159–4167.
4. Li L, Li W. Epithelial-mesenchymal transition in human cancer: Comprehensive reprogramming of metabolism, epigenetics, and differentiation. Pharmacol Ther. 2015;150(1):33–46.
5. Janda CY, Dang LT, You C, Chang J, De WL, Zhong ZA, Yan KS, Marcioe O, Siepe D, Li X, Moody JD, et al. Surrogate Wnt agonists that phenocopy canonical Wnt/β-catenin signaling. Nature. 2017;545(7653):234–237.
6. Rapettimauss R, Bustos V, Thomas W, Mcbryan J, Harvey H, Lajczak N, Madden SF, Pellissier B, Borgese F, Soriani O, Harvey BJ. Bidirectional KCNQ1:β-catenin interaction drives colorectal cancer cell differentiation. P Natl Acad Sci U S A. 2017;114(16):4159–4164.
7. Lo R, Leung C, Chan K, Ho D, Wong C, Lee T, Ng IO. Cripto-1 contributes to stemness in hepatocellular carcinoma by stabilizing dishevelled-3 and activating Wnt/β-catenin pathway. Cell Death Differ. 2018;9(3):1426–1441.
8. Panda PK, Naik PP, Praharaj PP, Meher BR, Gupta PK, Verma RS, Maiti TK, Shanmugam MK, Chinnathambi A, Alharbi SA, Sethi G, et al. Abrus agglutinins stimulates BMP-2-dependent differentiation through autophagic degradation of β-catenin in colon cancer stem cells. Mole Carcinog. 2018;57(5):664–677.
9. Gao Y, Chen Z, Wang R, Tan X, Huang C, Chen G, Chen Z. LXRα promotes the differentiation of human gastric cancer cells through inactivation of Wnt/β-catenin signaling. J Cancer. 2019;10(1):156–167.
10. Matsushita K, Morello F, Zhang Z, Masuda T, Iwanaga S, Steffenes KN, Gustafsson JÅ, Pratt RE, Dzau VJ. Nuclear hormone receptor LXRα inhibits adipocyte differentiation of mesenchymal stem cells with Wnt/β-catenin signaling. Lab Invest. 2016;96(2):230–238.
11. Smulski CR, Decossas M, Chekkat N, Beyrath J, Willen L, Guichard G, Lorenzetti R, Rizzi M, Eibel H, Schneider P, Fourmel S, et al. Hetero-oligomerization between the TNF receptor superfamily members CD40, Fas and TRAILR2 modulate CD40 signalling. Cell Death Dis. 2017;8(2):2601–2611.
12. Tanikawa C, Ri C, Kumar V, Nakamura Y, Matsuda K. Cross-talk of EDA-A2/XEDAR in the p53 Signaling Pathway. Mol Cancer Res. 2010;8(6):855–863.
13. Vial J, Royet A, Cassier P, Tortereau A, Dinvatn S, Maillet D, Gratadou-Hupon L, Creveaux M, Sadier A, Tondeur G, Léon S, et al. The Ectodysplasin receptor EDAR acts as a tumor suppressor in melanoma by conditionally inducing cell death. Cell Death Differ. 2018;26(3):443–454.
25. Chang B, Punj V, Shindo M, Chaudhary PM. Adenoviral-mediated gene transfer of ectodysplasin-A2 results in induction of apoptosis and cell-cycle arrest in osteosarcoma cell lines. Cancer Gene Ther. 2007;14(11):927–933.

26. Peng Y, Zhang X, FENG X, Fan X, Jin Z. The crosstalk between microRNAs and the Wnt/β-catenin signaling pathway in cancer. Oncotarget. 2015;8(8):14089–14106.

27. Fan D, Ren B, Yang X, Liu J, Zhang Z. Upregulation of miR-501-5p activates the wnt/β-catenin signaling pathway and enhances stem cell-like phenotype in gastric cancer. J Exp Clin Canc Res. 2016;35(1):177–185.

28. Lemieux E, Cagnol S, Beaudry K, Carrier J, Rivard N. Oncogenic KRAS signalling promotes the Wnt/β-catenin pathway through LRP6 in colorectal cancer. Oncogene. 2015;34(38):4914–4927.

29. Jia Y, Yang Y, Liu S, Herman JG, Lu F, Guo M. SOX17 antagonizes WNT/β-catenin signaling pathway in hepatocellular carcinoma. Epigenetics. 2010;5(8):743–749.

30. Huang J, Xiao D, Li G, Ma J, Chen P, Yuan W, Hou F, Ge J, Zhong M, Tang Y, Xia X, et al. EphA2 promotes epithelial–mesenchymal transition through the Wnt/β-catenin pathway in gastric cancer cells. Oncogene. 2014;33(21):2737–2747.

31. Margot Z. CD44: can a cancer-initiating cell profit from an abundantly expressed molecule? Nat Rev Cancer. 2011;11(4):254–267.

32. Zhu X, Morales FC, Agarwal NK, Dogruluk T, Gagea M, Georgescu MM. Moesin is a glioma progression marker that induces proliferation and Wnt/β-catenin pathway activation via interaction with CD44. Cancer Res. 2013;73(3):1142–1155.

33. Liu XF, Li XY, Zheng PS, Yang WT. DAX1 promotes cervical cancer cell growth and tumorigenicity through activation of Wnt/β-catenin pathway via GSK3β. Cell Death Dis. 2018;9(3):339.

34. Mao J, Liang Z, Zhang B, Yang H, Li X, Fu H, Zhang X, Yan Y, Xu W, Qian H. UBR2 enriched in P53-/mBMMSC-Exosome promoted gastric cancer progression via Wnt/β-catenin pathway. Stem Cells. 2017;35(11):2267–2279.

35. Kai-Ting C, Kelig P, Yuan-Hau T, Yu-Hsuan W, Jui-Yu H, Ko-Hsun L, Guguen-Guillouzo C, Wang HW. Liver X receptor α (LXRα/NR1H3) regulates differentiation of hepatocyte-like cells via reciprocal regulation of HNF4α. J Hepatol. 2014;61(6):1276–1286.

36. Didonato JA, Mercurio F, Karin M. NF-κB and the link between inflammation and cancer. Immunol Rev. 2012;246(1):379–400.

37. Capece D, Verzella D, Tessitore A, Alesse E, Capalbo C, Zazzaroni F. Cancer secretome and inflammation: The bright and the dark sides of NF-κB. Semin Cell Dev Biol. 2017;78(1):51–61.

38. Taniguchi K., Karin M. NF-κB, inflammation, immunity and cancer: coming of age. Nat Rev Immunol. 2018;18(5):309–324.

39. Klein U, Ghosh S. The Two Faces of nf-κB signaling in cancer development and therapy. Cancer Cell. 2011;20(5):556–558.

40. Giampazolias E, Zunino B, Dhayade S, Bock F, Cloix C, Cao K, Roca A, Lopez J, Ichim G, Proïcs E, Rubio-Patiño C, et al. Mitochondrial permeabilization engages NF-κB-dependent anti-tumour activity under caspase deficiency. Nat Cell Biol. 2017;19(9):1116–1129.